15 Christiaens L， Macchi L， Herpin D， et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res. 2002; 108（2-3）: 115-119.
16 Mattiasson I， Lethagen S， Hillarp A. Increased sensi-tivity to ADP-aggregation in aspirin treated patients with recurrent ischemic stroke? Int Angiol. 2003; 22（3）: 239-242.
17 Payne DA， Jones CI， Hayes PD， et al. Platelet inhibi-tion by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance? Thromb Haemost. 2004; 92（1）: 89-96.
18 Mirkhel A， Peyster E， Sundeen J， et al. Frequency of aspirin resistance in a community hospital. Am J Cardi-ol. 2006; 98（5）: 577-579.
19 Macchi L， Christiaens L， Brabant S， et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 （GP IIIa） polymorphism but not with C807T （GP Ia/IIa） and C-5T Kozak （GP Ibalpha） polymorphisms. J Am Coll Cardiol. 2003; 42（6）: 1115-1119.
20 Gum PA， Kottke-Marchant K， Poggio ED， et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001; 88（3）: 230-235.
21 Jagroop IA， Mikhailidis DP. Doxazosin， an alpha1- adrenoceptor antagonist， inhibits serotonin-induced shape change in human platelets. J Hum Hypertens. 2001; 15（3）: 203-207.